Contact Now
Send Message
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Shaanxi Kaishi Biotechnology Co., Ltd
$650
1-199 Kilogram
$600
200-499 Kilogram
$550
≥500 Kilogram
Product Description
Urolithin A is a naturally occurring gut microbiota-derived metabolite formed from dietary ellagitannins and ellagic acid, and it is studied for its role in mitochondrial function and healthy aging. As a specialized nutritional ingredient, it is used in dietary supplement development, particularly for healthy aging, active lifestyle, and muscle-function-oriented formulations.
Urolithin A is a defined organic compound belonging to the benzo-coumarin family of metabolites. It can be produced by intestinal microorganisms from ellagitannin-rich foods, including pomegranates and certain nuts and berries, although the ability to produce it varies among individuals. Commercial urolithin A is generally supplied as a purified ingredient rather than a conventional botanical extract.
For nutritional ingredient buyers, urolithin A offers a distinct formulation option for premium healthy-aging and active-nutrition products. Its specification should clearly define compound identity, assay basis, purity, analytical method, and physical form. These details are particularly important when comparing high-purity bulk powders, research-grade materials, and finished supplement preparations.
Urolithin A is a microbial metabolite associated with the metabolism of ellagitannins and ellagic acid. These precursor compounds occur in foods such as pomegranates, walnuts, and some berries. Human intestinal microbiota differ in their ability to convert these dietary compounds into urolithins, so consuming precursor-rich foods does not guarantee a consistent level of urolithin A production.
In scientific research, urolithin A has attracted interest for its relationship with mitophagy, the cellular process involved in removing and recycling damaged mitochondria. Mitochondrial quality control is relevant to research on cellular energy metabolism, muscle function, and healthy aging. These research areas should not be interpreted as proof that every commercial ingredient or finished supplement produces a specific clinical outcome.
| Item | Specification |
|---|---|
| Product Name | Urolithin A |
| Common Name | Urolithin A; 3,8-Dihydroxyurolithin |
| CAS Number | 1143-70-0 |
| Molecular Formula | C13H8O4 |
| Molecular Weight | 228.20 g/mol |
| Chemical Category | Benzo-coumarin derivative; gut microbiota-derived metabolite |
| Appearance | Typically a white to off-white or pale yellow powder, depending on purity and physical characteristics. |
| Assay / Purity | High-purity commercial grades commonly target 98% or 99%; the exact grade and acceptance limits should be defined in the applicable product specification. |
| Identification | HPLC chromatographic profile, supported by appropriate spectroscopic or mass-spectrometric identification where required. |
| Test Method | HPLC or UPLC using a validated method suitable for urolithin A; LC-MS may be used for identity confirmation. |
| Solubility | Limited water solubility under typical conditions; solubility and dispersion depend on pH, solvent system, particle characteristics, and formulation technology. |
| Common Product Forms | Purified bulk powder and customized nutritional ingredient preparations. |
| Typical Applications | Dietary supplements, healthy-aging formulations, active-nutrition products, and specialized nutritional ingredient research. |
| Particle Size | Grade-dependent; can be specified according to blending, encapsulation, tableting, or other manufacturing requirements. |
| Storage | Store in a tightly sealed container in a cool, dry place, protected from direct sunlight, excessive heat, and moisture. Follow the product-specific storage instructions. |
| Shelf Life | Common planning reference is up to 24 months under recommended storage conditions, subject to applicable stability data and the product specification. |
| Packaging | Common bulk packaging includes sealed 1 kg or 5 kg barrier bags and 25 kg fiber drums, with packaging selected according to order size and handling requirements. |
| Quality Documentation | COA, TDS, SDS, and relevant analytical records can be requested for purchasing, supplier qualification, and incoming quality review. |
These research areas do not establish that every urolithin A ingredient or supplement delivers a particular health outcome. Finished-product claims, recommended use levels, and labeling should be supported by appropriate evidence and reviewed against the regulations of the intended market.
Urolithin A is used in the development of premium nutritional supplements positioned around healthy aging and cellular health. Buyers should assess the ingredient's purity, dosage-form compatibility, stability, and suitability for the target market before incorporating it into a finished product.
Brands developing products for active adults may evaluate urolithin A for formulations related to muscle function and physical performance research. Formulation design should distinguish ingredient research findings from claims substantiated for the finished supplement and its intended population.
Purified urolithin A powder can be evaluated for capsule and tablet production. Its limited water solubility makes powder flow, particle characteristics, blending uniformity, and dissolution behavior relevant formulation considerations. Pilot-scale trials can help establish suitable excipients and processing conditions.
Urolithin A may be incorporated into selected powder blends or customized nutritional products when its chemical compatibility, processing behavior, and finished-product stability have been evaluated. Any combination with other active ingredients should be assessed for compatibility, analytical interference, and target-market requirements.
The most important procurement distinction is between the identity and purity of the raw compound and the performance of the finished dosage form. A high HPLC assay can support raw-material quality assessment, but it does not by itself establish solubility, absorption, stability in a blend, or the effectiveness of a finished supplement.
| Evaluation Point | What Buyers Should Check | Why It Matters |
|---|---|---|
| Compound identity | Confirm Urolithin A, CAS 1143-70-0, and appropriate identification data. | Prevents confusion with other urolithins, precursor compounds, or mixed botanical ingredients. |
| Purity and assay basis | Review the stated assay percentage, chromatographic method, calculation basis, and batch-specific COA. | Ensures the reported purity is interpretable and comparable across suppliers. |
| Physical properties | Evaluate powder appearance, particle size, flow, and blending performance. | These factors can affect capsule filling, tablet compression, blend uniformity, and manufacturing efficiency. |
| Solubility and dissolution | Assess performance in the intended solvent or dosage form and request relevant technical guidance. | Limited water solubility can affect formulation development and the behavior of the finished product. |
| Stability and packaging | Review storage conditions, moisture protection, packaging compatibility, and available stability information. | Helps establish suitable handling conditions and support shelf-life planning. |
| Quality and regulatory documentation | Review COA, TDS, SDS, relevant contaminant testing, and market-specific regulatory requirements. | Supports supplier qualification, incoming inspection, and compliant commercialization. |
A 98% or 99% specification should be assessed in the context of the assay method, acceptance limits, manufacturing requirements, and cost-in-use. A nominally higher purity does not automatically mean a finished supplement will perform better. Buyers should compare batch-specific chromatograms, impurity profiles where available, analytical methods, and the consistency of the supplied grade.
For capsule and tablet manufacturers, the most suitable material is not necessarily the powder with the highest headline assay. Powder flow, blend uniformity, excipient compatibility, and finished-product testing may be equally important. For premium ingredient programs, a clearly defined specification and reproducible batch documentation are often more useful than an unsupported purity claim.
Urolithin A can be supplied in packaging formats suited to sampling, formulation trials, and bulk manufacturing. Common options include sealed barrier bags for smaller quantities and fiber drums for larger orders. Packaging should protect the powder from moisture and environmental exposure during storage and transport. Final pack sizes and handling instructions should match the supplied specification and commercial requirements.
Urolithin A can be considered for customized nutritional supplements, including capsules, tablets, and selected powder formulations. OEM and private-label projects may involve dosage-form selection, excipient evaluation, product specification development, packaging, and label adaptation. Formulation feasibility, stability, ingredient compatibility, dosage substantiation, and regulatory review should be completed before commercialization.
A quality-control plan for urolithin A should focus on compound identity, assay consistency, impurity control, and suitability for the intended nutritional application. Relevant controls may include:
Acceptance criteria should be established in the agreed specification. Raw-material testing should be supplemented by finished-product testing and a regulatory assessment appropriate to the intended use and market.
Ellagic acid is a dietary polyphenol found in foods such as pomegranates and certain nuts and berries. Urolithin A is a metabolite that can be produced when intestinal microorganisms transform ellagitannins and ellagic acid. They are chemically distinct compounds and should not be treated as interchangeable ingredients in product specifications or formulation calculations.
HPLC or UPLC is commonly suitable for evaluating urolithin A assay when the analytical method has been validated for the material. Identity may be supported by spectroscopic or mass-spectrometric techniques. Buyers should review the actual assay basis, acceptance limits, chromatographic information, and batch-specific COA rather than relying only on a headline purity percentage.
Purified urolithin A can be evaluated for capsule and tablet formulations. Suitability depends on powder flow, particle properties, blending uniformity, excipient compatibility, dissolution performance, and finished-product stability. Pilot production and dosage-form testing are recommended before commercial scale-up.
Request a batch-specific COA, TDS, SDS, and relevant analytical identity and assay records. Depending on the grade and intended market, review impurity data, heavy metal testing, microbiological results, residual solvent information, and stability documentation where applicable. Regulatory suitability should be assessed separately for the intended product and destination market.
Urolithin A is a specialized nutritional ingredient attracting interest in mitochondrial-function research, healthy-aging product development, and active-nutrition formulations. Effective sourcing requires verified compound identity, a clearly defined assay basis, suitable analytical documentation, and evaluation of formulation performance beyond raw-material purity alone. Contact us today to request samples, a COA, technical documents, and a wholesale quotation for urolithin A.
Packaging & Delivery
| Selling Units: | Kilogram |
|---|
The file is encrypted. Please fill in the following information to continue accessing it
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.